• Cy3 Rabbit Anti-Goat IgG (H+L) Antibody: Technical Applicati

  2026-06-18

  The Cy3 Rabbit Anti-Goat IgG (H+L) Antibody addresses the need for sensitive, specific detection of goat IgG primaries in fluorescence-based immunodetection workflows. It is not suitable for use with non-goat primary antibodies or outside validated applications such as ICC/IF, IHC, flow cytometry, and ELISA.

• Homoharringtonine: Cytotoxic Alkaloid Workflows in Cancer &

  2026-06-18

  Homoharringtonine bridges oncology and virology with powerful, reproducible workflows for both leukemia research and SARS-CoV-2 antiviral studies. Learn stepwise protocols and troubleshooting strategies to maximize its cytotoxic and translational impact.

• Matrix Metalloproteinase-Responsive Hydrogel for Localized F

  2026-06-17

  This study introduces an injectable, matrix metalloproteinase-responsive nanoparticle hydrogel scaffold for sustained, localized delivery of RANKL inhibitors in fibrous dysplasia. The approach addresses the need for lesion-specific therapy while minimizing systemic exposure, demonstrating significant disease attenuation in a mouse model.

• Losartan as an Angiotensin II Receptor Antagonist in Vascula

  2026-06-17

  Losartan’s selective AT1 receptor blockade enables precise investigation of angiotensin II-driven vascular and renal mechanisms, making it invaluable for hypertension and podocyte injury studies. This guide distills experimental workflows, optimization strategies, and actionable troubleshooting tips for leveraging Losartan in advanced cardiovascular physiology research.

• FGF4-FGFR1 Axis Preserves Podocyte Function in Diabetic Kidn

  2026-06-16

  This study identifies podocyte-secreted FGF4 as a critical regulator of glomerular health in diabetic kidney disease (DKD), demonstrating that FGF4-FGFR1 signaling preserves podocyte survival and glomerular function via AMPK-FOXO1 pathways. The findings highlight a potential therapeutic target distinct from conventional angiotensin II receptor antagonists for DKD intervention.

• Mithramycin A in Cancer Biology: Mechanistic Depth and Resea

  2026-06-16

  Explore Mithramycin A, an anticancer antibiotic, through a deep dive into its selective DNA binding, polymerase inhibition, and emerging roles in leukemia and gene regulation research. This article offers advanced protocols and unique insights into assay optimization.

• Veratridine in Next-Gen Cardiac and Neuro Assays: Mechanism

  2026-06-15

  Explore how Veratridine, a potent voltage-gated sodium channel opener, is revolutionizing chamber-specific cardiac modeling and neurophysiology assays. This article provides a deep dive into its mechanism and unique role beyond standard sodium channel research.

• Bsa I (RNase-free): Practical Guide for Gene Cloning Workflo

  2026-06-15

  Bsa I (RNase-free) is designed for DNA cleavage in workflows where RNA integrity must be preserved, such as gene cloning and recombinant DNA technology. It is not suitable for diagnostic or clinical use, and is best reserved for sensitive molecular biology research requiring RNase-free conditions.

• Engineered KR-12 Peptides: Origami Strategies and Antimicrob

  2026-06-14

  The reference review details the structural engineering and application spectrum of KR-12, the smallest active fragment of human LL-37. Innovations include origami-inspired peptide modifications that enhance antimicrobial, anti-biofilm, and immunomodulatory functions, providing new directions for targeting drug-resistant pathogens.

• Fasudil (HA-1077) HCl: Applied ROCK Inhibition in Cancer Mod

  2026-06-13

  Fasudil (HA-1077) HCl from APExBIO enables precise Rho/ROCK pathway inhibition for cell proliferation, migration, and apoptosis studies in cancer and hematological models. This article provides optimized experimental workflows, troubleshooting strategies, and actionable insights for integrating Fasudil into advanced cell signaling research.

• Ginsenoside Rg1: Protocols and Troubleshooting in Neuroprote

  2026-06-12

  Ginsenoside Rg1, a Panax-derived triterpene saponin, is redefining experimental neuroprotection through precise modulation of neuroimmune pathways. This guide delivers protocol-driven insights, troubleshooting strategies, and actionable workflows for apoptosis and inflammation research, all anchored by recent advances in post-anesthesia neuroprotection.

• EDI3 Inhibition Reduces Tumor Growth in HER2+ Breast Cancer

  2026-06-12

  Keller et al. identified glycerophosphodiesterase EDI3 as a metabolic vulnerability in ER-HER2+ breast cancer cells that are resistant to HER2-targeted therapy. Their study demonstrates that targeting EDI3 impairs tumor cell viability and growth, suggesting a novel metabolic intervention point for overcoming therapeutic resistance.

• Glabridin-Gold(I) Complex 6d: A Synergistic Immunomodulator

  2026-06-11

  This study introduces a glabridin-gold(I) complex (6d) that synergistically targets TrxR and MAPK pathways to enhance antitumor immunity in liver cancer. By modulating both tumor immunogenicity and the immunosuppressive microenvironment, 6d offers a promising strategy to boost immunotherapy efficacy.

• Hydroxyl Radical Degradation Mechanisms of Dimetridazole Exp

  2026-06-11

  This study delivers a quantum chemical analysis of how hydroxyl radicals degrade Dimetridazole (1,2-Dimethyl-5-nitroimidazole) in water, with detailed mechanistic and kinetic data. The findings reveal both efficient breakdown and transient toxicity risks, providing a foundation for improved removal strategies and environmental risk assessment.

• Catalpol Inhibits Liver Fibrosis via EphA2/FAK/Src Pathway M

  2026-06-10

  This study reveals catalpol’s ability to attenuate liver fibrosis by targeting metabolic reprogramming in hepatic stellate cells through direct inhibition of the EphA2/FAK/Src signaling axis. The findings underscore the therapeutic potential of modulating Src kinase pathways in fibrotic disease and provide mechanistic clarity for future antifibrotic drug design.

15321 records 2/1022 page Previous Next 12345 下5页 Last page